获取途径

作者

Weili Li, Sifei Wang, Lan Liu, Jiahao Chen, Jing Lan, Jiayue Ding, Zhiying Chen, Shuhua Yuan, Zhifeng Qi, Ming Wei, Xunming Ji

作者单位

Affiliations ¹ Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China (W.L.). ² Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders (W.L., J.L., M.W., X.J.). ³ Clinical College of Neurology, Neurosurgery and Neurorehabilitation, Tianjin Medical University, China (S.W.). ⁴ Department of Neurosurgery, Tianjin Huanhu Hospital, China (S.W., M.W.). ⁵ School of Statistics, University of Minnesota at Twin Cities, Minneapolis (L.L.). ⁶ Department of Neurobiology (J.C.). ⁷ Department of Neurology, Tianjin Medical University General Hospital, China (J.D.). ⁸ Department of Neurology, Jiujiang University Affiliated Hospital, China (Z.C.). ⁹ Cerebrovascular Diseases Research Institute, Xuanwu Hospital (S.Y., Z.Q.), Capital Medical University, Beijing, China. ¹⁰ Department of Neurosurgery, Xuanwu Hospital (X.J.), Capital Medical University, Beijing, China.

刊名

Stroke

年份

2024

卷号

Vol.55 No.6

页码

1468-1476

ISSN

1524-4628

关键词

cerebral infarction duration of therapy hyperoxia ischemic stroke neuroprotective agents.

分类号

616.1

摘要

Background: Normobaric hyperoxia has neuroprotective effects in acute ischemic stroke. Thus, we aimed to identify the optimal NBO treatment duration combined with endovascular treatment. Methods: This is a single-center, randomized controlled, open-label, blinded-end point dose-escalation clinical trial. Patients with acute ischemic stroke who had an indication for endovascular treatment at Tianjin Huanhu Hospital were randomly assigned to 4 groups based on NBO therapy duration: control group...更多

Background: Normobaric hyperoxia has neuroprotective effects in acute ischemic stroke. Thus, we aimed to identify the optimal NBO treatment duration combined with endovascular treatment. Methods: This is a single-center, randomized controlled, open-label, blinded-end point dose-escalation clinical trial. Patients with acute ischemic stroke who had an indication for endovascular treatment at Tianjin Huanhu Hospital were randomly assigned to 4 groups based on NBO therapy duration: control group ; NBO-2h group ; NBO-4h group ; and NBO-6h group . The primary outcome was cerebral infarction volume at 72 hours after randomization using an intention-to-treat analysis model. The primary safety outcome was the 90-day mortality rate. Results: Between June 2022 and September 2023, 100 patients were randomly assigned to the following groups: control group , NBO-2h group , NBO-4h group , and NBO-6h group . The 72-hour cerebral infarct volumes were 39.4±34.3 mL, 30.6±30.1 mL, 19.7±15.4 mL, and 22.6±22.4 mL, respectively . The NBO-4h and NBO-6h groups both showed statistically significant differences compared with the control group. Compared with the control group, both the NBO-4h and NBO-6h groups showed significant differences in the National Institutes of Health Stroke Scale scores at 24 hours, 72 hours, and 7 days, as well as in the change of the National Institutes of Health Stroke Scale scores from baseline to 24 hours. Additionally, there were no significant differences among the 4 groups in terms of 90-day mortality rate, symptomatic intracranial hemorrhage, early neurological deterioration, or severe adverse events. Conclusions: The effectiveness of NBO therapy was associated with oxygen administration duration. Among patients with acute ischemic stroke who underwent endovascular treatment, NBO therapy for 4 and 6 hours was found to be more effective. Larger-scale multicenter studies are needed to validate these findings. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05404373.收起

学科

【SCI学科】CLINICAL NEUROLOGY;PERIPHERAL VASCULAR DISEASE 【ESI学科】NEUROSCIENCE & BEHAVIOR

影响因子

2018年:6.046;2017年:6.239;2016年:6.032;2015年:5.787;2014年:5.761

文献类型

期刊